Introduction copies per cell) in the cells of proximal surface human Cystic fibrosis (CF) is a common, lethal recessive herediairway epithelium, with somewhat higher expression tary disorder caused by mutations of the cystic fibrosis exhibited by serous cells in the glands and surface epitransmembrane conductance regulator (CFTR) gene, a thelium. [27] [28] [29] Despite this, ongoing strategies for human 250 kb, 27 exon segment of chromosome 7. [1] [2] [3] [4] The CFTR CF gene therapy utilize moderate to highly active gene product functions as a cAMP-regulated Cl − channel constitutive viral or eukaryotic promoters to drive the on the apical surface of epithelial cells. 5, 6 When there are CFTR cDNA, such as the adenovirus major late mutations of the two parental CF genes, the epithelial promoter/tripartite leader, cytomegalovirus immediatecells are unable to modulate Cl − secretion via the cAMP early promoter/enhancer, Rous sarcoma virus long terpathway. 7, 8 The major clinical manifestations of CF are on minal repeat (RSV), adenovirus E1a promoter, SV40 early the airway epithelial surface, chronic mucus production, promoter and the chicken ␤-actin promoter.
9-17,21,23,24, 29, 30 infection and inflammation, and progressive respiratory Although there have been no adverse consequences of failure. 4 chronic excess CFTR expression noted in any CF gene Based on the knowledge that in vitro transfer of the therapy trial, there is in vitro evidence that chronic overnormal human CFTR cDNA to epithelial cells derived expression of the CFTR cDNA may adversely affect some from individuals with CF will permit the cells to secrete cell functions. 31 Cl − in response to cAMP, 9-11 there has been intense interest Based on these considerations, the present study is in strategizing approaches to treating CF by transferring the directed toward evaluating the concept that a regulatable CFTR cDNA to the airway epithelium in vivo. [11] [12] [13] [14] [15] [16] The promoter could be utilized to control the normal CFTR human CFTR cDNA has been successfully transferred to cDNA transferred to the airway epithelium with a gene the airway epithelium of experimental animals using transfer vector. To demonstrate the feasibility of this adenovirus, adeno-associated virus and liposome-plasstrategy, we have constructed an Ad gene transfer vector mid vectors, [11] [12] [13] [14] [15] [16] and to the human airway epithelium containing an expression cassette with the normal human with adenovirus 17, 18 and adeno-associated virus CFTR cDNA driven by CF126(CRE8), a chimeric provectors 19, 20 and human nasal epithelium with adenomoter comprised of a minimal sequence of the 5′-flanking virus [21] [22] [23] and liposome-plasmid vectors. [24] [25] [26] region of the human CFTR cDNA together with multiple The target for gene therapy for the respiratory manifesrepeats of the consensus sequence of cAMP response tations of CF is the airway epithelium. The endogenous elements. 32 We hypothesize that this expression cassette will confer a low basal level of CFTR activity on the CF cells, but when cAMP levels are raised within the cell, the cassette will increase expression of the normal CFTR (Figure 2a ). At 0.3 m forskolin, the CFTR mRNA levels
Results
were relatively low, but were significantly elevated above the CFTR mRNA levels in control cells that were not Ad-vector derived CFTR mRNA up-regulation treated with forskolin (P Ͻ 0.0001, both MOI). Maximal Consistent with the previous observations that the chim-CFTR mRNA levels were observed at 10 m forskolin eric promoter utilizing a 126-bp sequence from the 5′-(six-to 15-fold above basal levels with no forskolin, 10 flanking region of the human CFTR gene with the and 5 MOI, respectively; P Ͻ 0.0001, both MOI). addition of eight repeats of cAMP responsive elements Evaluation of the time-dependency of the CFTR mRNA (CF126(CRE8) promoter) provides a low basal level of levels with the amount of forskolin (10 m) including gene expression, that can be up-regulated with an maximal CFTR mRNA levels demonstrated up-reguincrease in intracellular cAMP level in airway epithelial lation of CFTR that lasted 1 to 2 days (Figure 2b ). Cells cells in vitro and in vivo, 32 Northern analysis of total RNA infected with the AdCF126(CRE8).CFTR vector, with no from IB3 cells infected with the AdCF126(CRE8).CFTR addition of forskolin, demonstrated a low level of CFTR resulted in a low level of CFTR mRNA transcripts, but mRNA transcripts that gradually accumulated over time. these were markedly elevated after 12 h incubation with
In marked contrast, IB3 cells infected with the forskolin (Figure 1 ). Cells infected with the control vector, AdNull, demonstrated no detectable CFTR transcripts either in the presence or absence of forskolin. Evaluation of an adenovirus vector using a constitutive viral promoter (AdMLP.CFTR) showed that CFTR mRNA transcripts level supported by the active MLP promoter was not affected by elevating intracellular cAMP (data not shown). The mRNA level for GAPDH, used as internal control, did not change in the presence of forskolin in cells infected with either the AdNull or AdCF126(CRE8).CFTR vector.
Quantitative analysis of the Northern blots demonstrated that CFTR mRNA transcript levels were elevated in response to varying doses of forskolin in a dose-related manner and increasing MOI of the Ad vector, with the increase in the relative CFTR mRNA level induced by forskolin proportional to the vector dose administered AdCF126(CRE8).CFTR vector that were exposed to forskolin at 24 h resulted in a rapid increase in CFTR mRNA transcripts levels, reaching a peak at 12 h after addition of forskolin (ie 36 h after infection), followed by a gradual decrease of the CFTR mRNA transcripts with a half-life of approximately 38 h (Figure 2b ). In contrast to infection with AdCF126(CRE8).CFTR, infection with AdNull yielded no increase in CFTR mRNA levels with or without the addition of forskolin.
cAMP-mediated CFTR function
With the knowledge that levels of CFTR mRNA transcript derived from an Ad-vector could be controlled by a raise in intracellular cAMP levels, we hypothesized that an increased expression of the newly transferred normal CFTR cDNA as a consequence of the increased CFTR mRNA level, would correct the defect in Cl − secretion exhibited by IB3 CF cells. As expected, IB3 cells infected with the control AdNull, did not demonstrate forskolinstimulated Cl − secretion with or without addition of forskolin to activate the CFTR protein ( Figure 3a ). This was independent of whether forskolin was added at 24 h and/or at 38 h.
Similarly, cells infected with AdCF126(CRE8).CFTR, but that had not been incubated with forskolin at 24 h after infection to increase the exogenous CFTR mRNA levels, did not exhibit correction of Cl − secretion when evaluated at 38 h, independent of whether or not forskolin was present at that time ( Figure 3b ). In contrast, cells infected with AdCF126(CRE8).CFTR vector that had been incubated with forskolin at 24 h to elevate CFTR mRNA transcripts exhibited increased Cl − secretion when evalu- 
added at 24 h and again at 38 h(̆). (b) AdCF126(CRE8).CFTR infection.
demonstrated a significant amount of Cl − secretion
The conditions and symbols are identical to that in (a).
responding to forskolin (Figure 4a ). IB3 cells infected with the AdCF126(CRE8).CFTR vector, but not preincuof CFTR mRNA expression, the CF phenotype of IB3 cells bated with forskolin at 24 h after infection (ie CFTR was corrected at the lowest MOI studied, and secretion of mRNA level was not increased, Figure 3 ) did not demonCl − was further improved at higher doses of Ad-vectors strate significant Cl − secretion in response to the addition (forskolin at 24 and 38 h, MOI 0.2 compared with MOI of forskolin at 38 h (PϾ0.2, both comparisons to unin-5, P Ͻ 0.02; at all MOI, P Ͻ 0.005 compared to all confected IB3 cells, and to the AdNull infected control cells, trols; Figure 5 ). Figure 4b) . In marked contrast, cells infected with the AdCF126(CRE8).CFTR vector that had been incubated with forskolin 24 h after infection to increase CFTR Discussion mRNA levels (Figures 3 and 4b ) demonstrated a significant increase in Cl − secretion without the addition of forControlled expression of transgene is a strategy to maximise effectiveness of the therapy, and to circumvent skolin at 38 h or with the addition of forskolin at 38 h (P Ͻ 0.05, compared to uninfected IB3 cells, and to all potential adverse side-effects of gene therapy where chronic overexpression of the protein product is not AdNull-infected controls). Interestingly, the addition of forskolin at 38 h evoked more Cl − secretion, ie control of required. Previous experiments have demonstrated that expression of reporter gene transferred in the context of relative Cl − secretion could be achieved at both the mRNA and cAMP levels (P Ͻ 0.05, AdCF126(CRE8).
an adenovirus vector could be controlled utilizing a chimeric, cAMP-sensitive promoter in the lung in vivo.
32
CFTR + forskolin at 24 h and 38 h compared with 24 h only). Consistent with the concept that relative correction The present study is directed toward evaluating the concept that the controlled transcription of a transgene could of Cl − secretion could be controlled by the relative level correlate with a regulated relevant biological response. CF was chosen as the target based on the following considerations: (1) the chimeric CRE promoter is known to function in the lung in vivo; (2) cAMP elevating agents can be safely administered to humans; and (3) CF is the most intensively studied target using adenovirus vectors, and CFTR expression would be an appropriate marker to evaluate the promoter function in vivo. Cystic fibrosis presents a logical target for gene therapy, and the airway epithelium, the site of the major clinical manifestations of the disease, is easily accessible to gene transfer strategies. Importantly, the abnormal CF biologic phenotype can be corrected in vitro and in vivo by transfer of the normal CFTR cDNA to the respiratory epithelium.
9-12,21-24, 30 In all of the ongoing human gene therapy strategies for CF, the major focus has been to demonstrate the feasibility of gene transfer, and thus all vectors have utilized expression cassettes containing constitutively acute viral or eukaryotic promoters.
17,21,23,35-38 Studies carried out in humans and experimental animals have suggested that safety and efficacy of adenovirus-mediated gene transfer is predominantly dependent on the host immune response to infected target cells.
11,13,16,17,22,23 Such immune response and inflammation derived from adenovirus is prominent and current adenovirus vector provides relatively shortterm gene expression, while respiratory manifestations of CF will require a long-term correction for effective therapy. It is possible that potential adverse effects of overexpressing exogenous CFTR protein on a chronic basis may have been clouded by the inflammatory reaction, and in planning for a long-term correction of the CFTR abnormality in humans, it is appropriate to consider the consequences of chronic overexpression of the CFTR cDNA in fibroblasts results in slower growth rates than the par-
(CRE8).CFTR infection (MOI 5). The conditions are identical to those
ental cells, 31 ie there could be a problem of chronic CFTR in Figure 2 .
overexpression on some cell functions. The present study is directed toward the logical next step, to use a promoter that provides control over expression of the transferred normal CFTR cDNA by pharmacologic agents that can be safely administered to the airway epithelium in vivo.
Use of a cAMP regulatable promoter
The choice of cAMP-regulatable promoter is based on the following considerations. First, the addition of ␤-adrenergic receptor agonist isoproterenol to primary tracheal epithelial cells increases cAMP levels by 10-to 14-fold in cells from normal patients and individuals with CF, 40 supporting the idea of using inhaled ␤-agonists as a useful stimulant to raise airway epithelial cAMP levels, thus activating the expression of a transferred gene under the control of the chimeric cAMP-responsive promoter. Second, ␤-adrenergic agonists are readily used in the management of patients with CF. 4 Finally, the CFTR protein has a relatively long half-life(18 h), 41 and thus only an intermittent production of normal CFTR protein by using inhaled cAMP-elevating pharmacologic agents 
IB3 cells or a function of MOI. The conditions of addition of forskolin at 24 and/or 38 h are as in Figures 3 and 4.
The concept of using a cAMP-responsive promoter to 32 be made to use the chimeric, cAMP-sensitive promoter for gene therapy to evaluate the concept in humans, studand it will also be associated with the activation of the newly synthesized CFTR as the chloride channel in vivo.
ies should be carried out to demonstrate that the promoter functions as a genetic switch for a longer period. In a previous study using the AdCFTR vector (containing the Ad MLP promoter driving the CFTR cDNA), the However, for such chronic studies to be carried out, the hurdle of host immune response that is involved in the amount of the newly synthesized CFTR protein detected by immunoprecipitation did not correlate with cAMPelimination of transferred expression cassette must be solved. induced CFTR function, probably due to the fact that very little CFTR protein is required to correct the CFTR defect in CF. 42 Based on this, the mRNA transcript level
Materials and methods
was reported to evaluate behavior of the chimeric CF126(CRE8) promoter in the presence and absence of Cell culture forskolin. Interestingly, once the chimeric CF126(CRE8) IB3 cells, 47 an immortalized respiratory epithelial cell line promoter is up-regulated, the resulting increased CFTR derived from an individual with CF, were cultured in expression and the cAMP stimulus is relatively long last-LHC-8 medium (Biofluids, Rockville, MD, USA) together ing, such that enhanced Cl − secretion is observed 18 h with endothelial cell growth supplement (15 g/ml; later, even without additional stimulus to activate CFTR Sigma, St Louis, MO, USA). Tissue culture dishes were function. Consistent with this, incubation of the HT-29 coated with fibronectin (10 g/ml; Calbiochem, La Jolla, colon carcinoma cell line with forskolin for 18 h up-regu-CA, USA), collagen (30 g/ml; Collagen Corporation, lates endogenous CFTR protein and activates the CFTR Fremont, CA, USA), and bovine serum albumin protein, resulting in an improved Cl − secretion. 43 While (10 g/ml; Biofluids). T84 cells (ATCC CCL 248), a colon our observations clearly demonstrate this is feasible with carcinoma-derived cell line known to have normal CFTR respiratory epithelial cells derived from individuals with functions, 34 were cultured in Dulbecco's modified Eagle's CF, it is not clear whether it is beneficial to use pharmacomedium (DMEM; Biofluids) containing 10% fetal bovine logical agents to activate the newly expressed CFTR proserum (FBS), 50 units/ml penicillin, and 50 g/ml streptein to treat respiratory manifestations of CF or whether tomycin. All cells were incubated at 37°C in a humidified the goal of gene therapy should be only to provide sufincubator containing 5% CO 2 . ficient CFTR expression to permit endogenous cAMP to control the CFTR protein. For example, the sustained Adenovirus vectors increase of intracellular cAMP level may down-regulate
To provide a regulatable expression of the normal human the newly synthesized CFTR protein. 44, 45 CFTR cDNA in the context of an Ad5-based, E1a
− , E3
− replication-deficient adenovirus (Ad) vector, an Chimeric CF126(CRE8) promoter for CF gene therapy expression cassette was constructed with the normal Northern analysis of the relative amount of CFTR mRNA human CFTR cDNA driven by CF126(CRE8), a cAMPderived from the AdCF126(CRE8).CFTR demonstrated inducible, chimeric promoter comprised of a minimal that the magnitude of increase in the CFTR transcripts is sequence of the 5′-flanking region of the human CFTR dose responsive to the cAMP-elevating agent.
gene (−126 bp) with eight repeats of consensus sequence Importantly, the chimeric CF126(CRE8) promoter is of cAMP-responsive elements. 32 To accomplish this, a sensitive to a wide range of cAMP elevating agents (0.3 recombination plasmid (pAdCF126(CRE8).CFTR) was to 30 m), supporting the idea of using cAMP-responsive constructed by inserting the chimeric, CF126(CRE8) propromoters for human in vivo gene therapy strategies. moter 32 and the 4.5 kb human CFTR cDNA 2 fused with Importantly, sufficient functional CFTR protein was a SV40 polyadenylation signal, followed by Ad5 expressed to correct CF phenotype of the cells infected sequences 9.3 to 16.1 MU used for recombination with (MOI 0.5 to 5) relevant to clinical gene transfer 17 consistthe right end of the Ad vector. 11 The Ad-vector ent with previous reports demonstrating that a low MOI (AdCF126(CRE8).CFTR) was generated by cotransfecting of an Ad vector expressing CFTR is sufficient to increase the transformed embryonic kidney cell line 293 (HEK 293, Cl − secretion in CF cells. 30 CRL 1573; ATCC) with the pAdCF126(CRE8).CFTR The chimeric CF126(CRE8) promoter has some 'basal' recombination plasmids and pBHG10, an Ad5-based activity at unstimulated state (4% of the RSV-LTR). This plasmid with the majority of the E3 region deleted. 48 The basal activity is similar to the level of endogenous CFTR Ad-vector was propagated in 293 cells and purified by gene transcription rate (6% of the ␤-actin gene cesium chloride density gradient ultracentrifugtranscription), and the activity of CFTR 5′-flanking fragation. 11,49,50 Ad.Null, an Ad5-based, replication-deficient ments studied in HT29 human colon carcinoma, and Ad-vector with the CMV promoter but not transgene in human lung cancer cells HS24 and Calu3. 42, 46 Since the the expression cassette, was used as control. 51 The titer basal promoter activity of the chimeric promoter can be of the virus stocks was determined by plaque-forming easily manipulated by changing the number of cAMP assay on 293 cells. 49 responsive element and length of CFTR 5′-fragment used, it is technically possible to generate other promoters with different basal activity and inducibility to exogenous Northern analysis IB3 cells were infected (90 min, 37°C) in a serum-free stimulants. 32 The present study was designed to demonstrate the medium (LHC-8 medium) with AdCF126(CRE8).CFTR or AdNull, at MOI of 5 to 10. After 24 h, forskolin (10 m; feasibility of controlling transcription of the transferred gene to provide a flexible control over the relevant bioSigma) was added to the culture medium to raise intra- analyses of Cl − secretion were carried out 38 h after infec-
